Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €0.49 EUR
Change Today +0.024 / 5.14%
Volume 0.0
R3X On Other Exchanges
Symbol
Exchange
NYSE Amex
As of 1:36 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

rexahn pharmaceuticals inc (R3X) Snapshot

Open
€0.46
Previous Close
€0.47
Day High
€0.49
Day Low
€0.45
52 Week High
01/12/15 - €0.81
52 Week Low
07/31/15 - €0.45
Market Cap
88.2M
Average Volume 10 Days
1.5K
EPS TTM
--
Shares Outstanding
179.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for REXAHN PHARMACEUTICALS INC (R3X)

Related News

No related news articles were found.

rexahn pharmaceuticals inc (R3X) Related Businessweek News

No Related Businessweek News Found

rexahn pharmaceuticals inc (R3X) Details

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer and other medical needs. The company has three clinical stage oncology candidates: Archexin, RX-3117, and Supinoxin (RX-5902), as well as a pipeline of preclinical compounds to treat multiple types of cancer. It has also developed proprietary drug discovery platform technologies in the areas of Nano-Polymer-Drug Conjugate Systems (NPDCS), nano-medicines, 3D-GOLD, and TIMES. Rexahn Pharmaceuticals, Inc. is based in Rockville, Maryland.

22 Employees
Last Reported Date: 03/16/15

rexahn pharmaceuticals inc (R3X) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $519.0K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $338.1K
Compensation as of Fiscal Year 2014.

rexahn pharmaceuticals inc (R3X) Key Developments

Rakesh Soni to Resign as President and Chief Operating Officer of Rexahn Pharmaceuticals, Inc., Effective July 21, 2015

On July 13, 2015, Rexahn Pharmaceuticals, Inc. was notified by Rakesh Soni, the company's President and Chief Operating Officer, that Mr. Soni will resign his employment with the company effective on July 21, 2015.

Rexahn Pharmaceuticals, Inc. Awards Patent in Japan for Novel Targeted Cancer Drug Delivery Platform

Rexahn Pharmaceuticals, Inc. announced that it was entitled Polymeric Systems for the Delivery of Anticancer Drugs for the Company's novel CPMA drug delivery platform. This new CPMA drug delivery platform technology, developed by Rexahn, enables more precise, targeted delivery of anti-cancer drugs directly into cancer cells. There is a significant unmet need in the oncology field for drugs which selectively target and kill cancer cells while sparing normal, healthy cells. By utilizing proprietary CPMA polymer drug delivery technology and combining it with currently approved anti-cancer drugs, hope to transport anti-cancer drugs directly into cancerous cells where their cytotoxic activity can be most effective, thereby increasing efficacy and minimizing the harmful side effects associated with traditional cancer therapy.

Rexahn Pharmaceuticals, Inc. Appoints Peter Brandt as Chairman of the Board

Rexahn Pharmaceuticals, Inc. announced the appointment of Peter Brandt as Chairman of the Board. Dr. Chang Ahn, Rexahn’s founder, will remain on the Board as Chairman Emeritus and will continue in his role as the company’s Chief Scientist. A Director of Rexahn since 2010, Mr.Brandt previously served as President and Chief Executive Officer of Noven Pharmaceuticals until its acquisition by Hisamitsu Pharmaceutical in 2009.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
R3X:GR €0.49 EUR +0.024

R3X Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for R3X.
View Industry Companies
 

Industry Analysis

R3X

Industry Average

Valuation R3X Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REXAHN PHARMACEUTICALS INC, please visit www.rexahn.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.